Benign Prostatic Hyperplasia, Primary Prostate Urothelial Cancer
Conditions
Brief summary
The aim of this study was to investigate plasma concentrations of one-carbon metabolites and phospholipid classes in participants with primary prostate cancer and those with benign hyperplasia. Moreover, the metabolites were studied in relation to tumor grade and age.
Detailed description
This observational study recruited participants with primary prostate cancer (cases) and those with benign hyperplasia (controls) before the surgery. Data on the outcomes of the surgery including the results of the biopsy investigation were collected. Blood samples were collected before the surgery in context of routine blood investigations. Blood plasma samples collected on ethylenediaminetetraacetic acid (EDTA) were used to measure concentrations of free choline, betaine, dimethylglycine, folate forms, S-adenosylhomocysteine, S-adenosylmethionine, homocysteine, cystathionine, and methylmalonic acid (MMA). Data on serum concentrations of prostate specific antigen (PSA) and the tumor grade and classification (Gleason Score system) were collected. The associations between the plasma concentrations of the metabolites and PSA or the Gleason score were studied. The concentrations of the metabolic markers were compared between the cases and the controls according to the age of the participants.
Interventions
OTHERPlasma concentration of choline
The exposure in this observational study is plasma concentrations of choline
Sponsors
Universität des Saarlandes
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
MALE
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Men participants * age \> 50 years * recently diagnosed with primary prostate cancer or benign hyperplasia
Exclusion criteria
* vitamin B supplementation (folic acid\> 400 µg / day; B12\> 10 µg / day; B6\> 10 mg / day) * renal failure * advanced liver disease * chronic alcohol consumption * metastases * methotrexate therapy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Plasma choline concentrations | through study completion, on average 1 year | Concentrations measured in plasma with liquid chromatography tandem mass spectrometry |
| Whole blood choline concentrations | through study completion, on average 1 year | Concentrations measured in plasma with liquid chromatography tandem mass spectrometry |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Plasma S-adenosylmethionine concentrations | through study completion, on average 1 year | Concentrations measured in plasma with liquid chromatography tandem mass spectrometry |
| Plasma betaine concentrations | through study completion, on average 1 year | Concentrations measured in plasma with liquid chromatography tandem mass spectrometry |
| Plasma and whole blood folate forms | through study completion, on average 1 year | Concentrations measured in plasma with liquid chromatography tandem mass spectrometry |
| Plasma homocysteine concentrations | through study completion, on average 1 year | Concentrations measured in plasma with liquid chromatography tandem mass spectrometry |
| Plasma methylmalonic acid concentrations | through study completion, on average 1 year | Concentrations measured in plasma with gas chromatography mass spectrometry |
| Plasma phospholipids | through study completion, on average 1 year | Concentrations measured in plasma with liquid chromatography tandem mass spectrometry after extraction |
Countries
Germany
Outcome results
None listed